Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002400 · ClinicalTrials.gov registry record · NA
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
A NA study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT00002400: Completed NA study, sponsored by Pharmacia and Upjohn.
NCT00002400 is a NA study that has completed, run by Pharmacia and Upjohn. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002400, a NA study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002400
The ClinicalTrials.gov registry entry for NCT00002400 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zidovudine is the first listed.
NCT00002400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002400 about?
NCT00002400 is a clinical study titled "A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients". The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with...
What is the current status of trial NCT00002400?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants.
What interventions are being tested in trial NCT00002400?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002400?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.